Aristopharma Ltd. has launched Dexalev O/Sol, which is the preparation of Dexamethasone Sodium Phosphate USP & Levofloxacin Hemihydrate USP.

Dexalev Ophthalmic Solution is a new fixed dose combination (FDC) of levofloxacin and dexamethasone offers only 7-days therapy approved by MHRA & EMA than other combination of topical antibiotic/corticosteroid. It is indicated for the treatment of eye infections caused by susceptible microorganisms and in the prevention of inflammation and bacterial infection that may occur after ocular surgery. 7 days combination (Dexamethasone & Levofloxacin) therapy followed by dexamethasone alone for next 7 days, prevents infections and reduces inflammation (95.2%) and pain & discomfort (95%) after ocular surgery. In the meantime, Levofloxacin is a fluoroquinolone antibacterial agent, has wide spectrum of activities against different gram-positive microorganisms (e.g. S. aureus MSSA, S. pyogenes, S. pneumoniae, viridans group streptococci), aerobic Gram-negative bacteria (e.g. E. coli, H. influenzae, M. catarrhalis, P. aeruginosa community isolates), other organisms (e.g. Chlamydia trachomatis). Beside this Dexalev is manufactured with European raw material from Spain.